Edition:
India

Profile: Arbutus Biopharma Corp (ABUS.OQ)

ABUS.OQ on NASDAQ Stock Exchange Global Select Market

2.40USD
17 May 2019
Change (% chg)

$-0.06 (-2.44%)
Prev Close
$2.46
Open
$2.43
Day's High
$2.49
Day's Low
$2.38
Volume
46,024
Avg. Vol
61,353
52-wk High
$12.50
52-wk Low
$2.18

Arbutus Biopharma Corp is a Canada-based biopharmaceutical company. The Company is dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). The Company develops a portfolio of drug candidates with multiple mechanisms of action that results in a combination therapy to cure HBV. In addition to its HBV pipeline, the Company actively licenses its Lipid Nanoparticle (LNP) technology to its industry partners. This technology represents a delivery technology in RNA interference (RNAi) therapeutic development, which has enabled several clinical trials and has been administered to hundreds of human subjects.

Company Address

Arbutus Biopharma Corp

100-8900 Glenlyon Pky
BURNABY   BC   V5J 5J8
P: +1604.4193200
F: +1604.4193201

Company Web Links